ClinicalTrials.gg
CompletedNCT02565641Updated Nov 2, 2016

A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer

A Phase 2 interventional study of Capecitabine and Gemcitabine in Pancreatic Cancer, sponsored by Hoffmann-La Roche. Completed at 7 sites in Korea, Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 81 studies testing capecitabine in Pancreatic Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. Capecitabine · Pancreatic Neoplasms.

Enrollment
20th of 79
63 · median 40
Started
2003
with 3 others
Phase 2
39 of 81
2 open now
Registered
66th of 81
by date
Lead sponsor
2 of 81
Hoffmann-La Roche

Among the 81 studies testing capecitabine in Pancreatic Neoplasms, this one is the 20th largest by enrollment of the 79 interventional ones that give a count, is one of 4 that started in 2003, is one of 39 in phase 2, and was the 66th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

4 of the 81 studies testing capecitabine in Pancreatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing capecitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of oral capecitabine plus intravenous (IV) gemcitabine in participants with locally advanced or metastatic pancreatic cancer. The anticipated time on study treatment is 3 to 12 months, and the target sample size is 56 individuals.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants 18 to 75 years of age
  • Locally advanced or pancreatic cancer

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy for pancreatic cancer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Capecitabine + Gemcitabine

    Participants will receive oral capecitabine (830 milligrams per meter-squared \[mg/m\^2\]) twice daily (BID) as intermittent treatment (Days 1 to 21 every 4 weeks \[q4w\]) along with IV infusion of gemcitabine (1000 mg/m\^2) once weekly as intermittent treatment (4-week cycles of 3-week treatment period and 1-week rest period).

    Drug: Capecitabine · Drug: Gemcitabine

Interventions

  • Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).

    Also known as: Xeloda

  • Gemcitabine will be administered at a dose of 1000 mg/m\^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).

06

What researchers measure

Primary outcomes

  1. Overall objective response rate

    Time frame: At the end of 6 cycles (24 weeks)

Secondary outcomes

  1. Duration of response

    Time frame: Up to approximately 3.5 years

  2. Time to disease progression

    Time frame: Up to approximately 3.5 years

  3. Time to response

    Time frame: Up to approximately 3.5 years

  4. Time to treatment failure

    Time frame: Up to approximately 3.5 years

  5. Overall survival

    Time frame: Up to approximately 3.5 years

  6. Incidence of adverse events

    Time frame: Up to approximately 3.5 years

07

Study locations

7 sites
  • Buchun, 420-021, Korea, Republic of
  • Daegu, Korea, Republic of
  • Seoul, 135-720, Korea, Republic of
  • Seoul, 137-702, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Seoul, 158-710, Korea, Republic of
  • Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2015
First posted
Oct 1, 2015
Start
Mar 2003
Primary completionActual
Sep 2006
CompletionActual
Sep 2006
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02565641
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 1, 2015
Start date
Mar 2003
Primary completion
Sep 2006
Completion
Sep 2006
Last update
Nov 2, 2016

Study contacts

Clinical Trials
Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Gemcitabine

Start the discussion